Effect of Cephalexin on Rosuvastatin Therapeutic Response in Rabbits with Induced Hyperlipidemia

Hyperlipidemia is the rise in plasma triglycerides and cholesterol; It is caused by a disruption in the metabolism of plasma lipoproteins. Either delayed breakdown or rapid synthesis might be the cause of the rise in lipoproteins or plasma lipids. This study was to determination how Cephalexin affected on the normal microbiota that could affect Rosuvastatin pharmacodynamic in rabbits with induced hyperlipidemia. 20 rabbits were divided into four groups were given a diet containing 1.3% cholesterol and 3% saturated fat for 40 days. the experiment was (pharmacodynamic): G1: Positive control with induced hyperlipidaemia; G2: Negative control; G3: Rosuvastatin-treated hyperlipidaemia group and G4: Rosuvastatin + Cephalexin combination treatment hyperlipidaemia group, 28 days. The Rosuvastatin therapy resulted in significant reductions in TC, TAG, LDL, VLDL and Fibrinogen levels and increases in HDL levels were markedly lowered. Furthermore, Short chain fatty acid decrease in the combination group and increases in TC, TAG, LDL, VLDL and Fibrinogen levels and increases in HDL levels comber with rosuvastatin alone. In conclusion combination Rosuvastatin with Cephalexin significantly unimproved the therapeutic efficacy of Rosuvastatin in hyperlipidaemia rabbits. The combination therapy exerts antagonism antioxidant, anti-inflammatory, and lipid-lowering effects.